Harvard study that reversed aging proves the power of gene expression
It was 1981. Ellen Langer was in a van with one research assistant, and a dozen elderly men. All were in their 70s and 80s, bound for a special location at a large monastery to the north.
The older men chatted about everyday life. Some were married and all were retired. Many had health conditions, mobility issues, and used canes. Two hours later, they arrived at a massive monastery in rural New Hampshire. It was a sparsely populated town. The men knew they were there for a study with Professor Langer, but knew nothing else of the intention.
Langer was an esteemed Harvard professor and hoping to do another groundbreaking study on aging and its interplay with psychology. She would succeed and reveal an insight that lives on to this day.
At the start of their study, they tested each man's grip strength, balance, cognition, memory, and mobility.
Then, Ellen began their plan for the week. There were movie screenings of films from these men's youth that they all loved.
They were brought together for discussions and memories from their teenage years, things that brought them happiness, and also frustration. They talked about the first dates they went on. On another night, the men listened to a radio broadcast from 1959: the Preakness race which was won by Royal Orbit. Another night, they screened Anatomy of a Murder.
The entire week was focused on things that reminded them of being young — and it paid off.
Each day, the men gained more energy and strength. They were moving more, and on the 5th day, they were even playing touch football, despite many of them having limps at the start of the study. When the men were tested at the end of the study, Ellen Langer was stunned: they had massive improvements in their mobility, cognition, and memory, and even reported less pain.
Langer's research revealed the power of labels and identity on our gene expression. Because men tapped into environmental cues and memories that reminded them of being young, their bodies came to life with a youthful vitality they had long missed.
What's amazing is that the men not only felt younger, their bodies physically morphed to resemble younger bodies. Langer suggests that the labels we are given by doctors, especially when we are sick, have huge consequences on the way we feel and live.
Her study built on the insight that genes can be changed in the way they manifest. Your beliefs can cause your body to express them like hidden members of an orchestra waiting for their turn. Langer did other groundbreaking studies, including showing that giving nursing home patients plants to take care of improved their health and cognitive function and even led to greater longevity.
She showed how people performed far better in memory tests when they had duties requiring memorization. You tend to live in a passive state of identity that is defined by your age, status, health, self-beliefs, and more. You subconsciously think, 'I am old so I'm supposed to be tired and forgetful.' It elevates those exact symptoms. The practice of optimism and tricking your own mind can alter how you perform in subtle, important ways.
A perfect example of the power of belief is how drugs often struggle to make it through clinical trials because they can't outperform placebo alternatives. One man was rushed to the hospital in fear of having overdosed (intentionally), only to have his doctor show up and tell him he was part of a clinical trial and was taking placebos.
His vitals all resembled him having overdosed and the doctors at the ER even believed it. It was all sugar pills. Another man was taking new blood pressure meds that significantly helped his hypertension, only to find out they were placebo. Such placebo effects have even been proven when the person knows it's a placebo.
No, this doesn't mean you should avoid doctors' orders or try to think your way to good health — but there is value in acting in good faith and believing in the things you want to happen, and that could even remotely be true about yourself.
It has become a massive cliche in the self-help world to talk about the power of belief. It's better to think of this as eliciting a response from your body that is already waiting dormant.
Per Langer's research, if you adopt the mindset of your younger, more vibrant self, think back on the things that brought you so much joy, and attempt to live like a younger person (minus all the indulgence), you could potentially inject massive energy into your life.
It starts with a leap of faith to believe things to be true.
As I look back at my own life, I have never found success in anything where I spent my time doubting myself over and over. There were plenty of times I felt insecure, and still do, but it was always underpinned by a feeling of, 'I can do this.' Anytime I've been sick, the act of thinking about how sick I am has only made it worse. It is like watching a needle go into your arm. It always hurts far worse, because you feed into it.
The mind matters more than most people already appreciate. There's virtue in getting drunk on self-belief in a strategic way, and in choosing to feel healthy and vibrant, to go out and be happy and do things, to value your intelligence for what it truly is rather than sit around and compare it to what it isn't.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
an hour ago
- Fox News
Harvard physicist says mysterious interstellar object could be nuclear-powered spaceship
A Harvard physicist who sounded the alarm earlier this month about a rare interstellar object passing through our solar system — and suggested it might be more than a comet — now says it could even be a nuclear-powered spaceship. The object, dubbed 3I/ATLAS, was first detected in early July by an Asteroid Terrestrial-impact Last Alert System (ATLAS) telescope in Chile. It marks only the third time an interstellar object has been observed entering our solar system, according to NASA. While NASA classified the object as a comet, Dr. Avi Loeb pointed out that an image showed an unexpected glow in front of the object rather than trailing behind it — something he called "quite surprising." In a blog post this week, Loeb wrote that the object's brightness profile cannot be explained by sunlight reflection or standard cometary outgassing. Instead, he suggested, 3I/ATLAS might be generating its own light — possibly from nuclear energy. "Alternatively, 3I/ATLAS could be a spacecraft powered by nuclear energy, and the dust emitted from its frontal surface might be from dirt that accumulated on its surface during its interstellar travel," Loeb wrote. "This cannot be ruled out, but requires better evidence to be viable." Loeb dismissed other natural power sources. A primordial black hole, he said, would generate only about 20 nanowatts — far too weak. A radioactive fragment from a supernova was highly unlikely given its rarity, and frictional heating from interstellar gas and dust was ruled out by momentum and density constraints. That leaves the simplest explanation: a central, compact, high-power source. The most natural way to achieve the gigawatt-level luminosity observed, Loeb noted, would be nuclear power. Still, Loeb does not claim the object is nuclear-powered. He stresses there is only one possible interpretation if natural models fail — and proving it would require more evidence. 3I/ATLAS is estimated at about 20 kilometers across, larger than Manhattan. Loeb has also raised questions about its unusual trajectory. "If you imagine objects entering the solar system from random directions, just one in 500 of them would be aligned so well with the orbits of the planets," Loeb told Fox News Digital earlier this month. The interstellar object, which comes from the center of the Milky Way, is also expected to pass near Mars, Venus, and Jupiter — another improbable coincidence, he said. "It also comes close to each of them, with a probability of one in 20,000," he said. According to NASA, 3I/ATLAS will reach its closest point to the sun — about 130 million miles away — on October 30. "If it turns out to be technological, it would obviously have a big impact on the future of humanity," Loeb said. "We have to decide how to respond to that."

Associated Press
3 hours ago
- Associated Press
Leading Researchers Reject FDA's Position, Find No Evidence of Harm From 7-OH in Response From Shaman Botanicals to FDA
Shaman Botanicals has issued a formal response to the FDA's recent warning letter on its 7-hydroxymitragynine (7-OH) products, backed by reports from leading researchers at Johns Hopkins, Harvard, UCLA, and other institutions. The company argues that current scientific evidence supports the safety of 7-OH, directly countering FDA's claims. Experts consulted — including those previously cited by FDA — stress that 7-OH should not be considered a public health crisis and that available data shows no evidence of overdose deaths, respiratory depression, or widespread dependence. The experts also emphasize that 7-OH is a naturally occurring kratom-derived compound, not synthetic, and that preclinical studies commissioned by Shaman found no serious toxicity. Collectively, the findings point toward a favorable safety profile and call for continued study rather than scheduling. Shaman Botanicals maintains its commitment to scientific transparency and consumer safety, urging FDA to follow the science. Key Points See the full Shaman Botanicals, LLC response below: Shaman Botanicals, LLC Responds to FDA Warning Letter with Scientific Reports by Renowned Experts Shaman Botanicals, LLC, a leading innovator in botanical wellness, has formally responded to a recent warning letter from the U.S. Food and Drug Administration (FDA) regarding its 7-hydroxymitragynine (7-OH) products. In support of its mission and to defend its products, attorneys for Shaman Botanicals have assembled an interdisciplinary team of renowned researchers, scientists, and clinicians to prepare reports that directly address the FDA's claims concerning 7-OH. 'The FDA asserts that there is insufficient information about the safety of our 7-OH products. However, the scientists consulted by our legal team have found that the evidence to date supports the safety of our products,' stated Stephen 'Vince' Sanders, II, founder of Shaman Botanicals. Scientists Cited by the FDA Express Concerns About the Scheduling of 7-OH Scientific reviews were provided by Dr. Kirsten Smith, PhD, widely regarded as the leading clinical researcher on kratom in the United States and an Assistant Professor at Johns Hopkins University, and Dr. Edward Boyer, MD, PhD, a Harvard-educated medical toxicologist with extensive experience in kratom research. The support for further study and regulation of 7-OH products by Drs. Smith and Boyer reflects a growing and dynamic shift in the scientific community's perspective on 7-OH. Work by Drs. Smith and Boyer was cited by the FDA in their recent report recommending the scheduling of 7-OH. Both Drs. Smith and Boyer are currently leading projects to better understand 7-OH use patterns in the United States. But, having looked at the latest data, they do not agree with FDA's position. Other scientists cited in Shaman's response to the FDA include Dr. Michael Levine, MD, a medical toxicologist educated at Chicago Medical School and an associate professor at the University of California-Los Angeles, recognized for his research in botanical toxicology, and Dr. Jackob Moskovitz, a Technion-Israel Institute of Technology-trained biochemist and internationally recognized expert in molecular biology. Drs. Levine and Moskovitz were provided with three preclinical studies commissioned by Shaman and asked to comment on them. Shaman's response also cited Dr. Glenn Prestwich, PhD, a Stanford-educated chemist and internationally recognized authority on natural products chemistry and chemical biology, and Dr. Andrew Monte, MD, PhD, the Associate Director of the Rocky Mountain Poison & Drug Center in Denver, Colorado, and an expert in nationwide monitoring for adverse events from opioids. 7-OH Should Not Be Considered a Public Health Crisis Dr. Smith strongly disagrees with the FDA's recent recommendation to schedule 7-OH. According to Dr. Smith, the use of 7-OH does not constitute a public health crisis. Furthermore, Dr. Smith asserts that, much like kratom, 7-OH currently offers a net benefit to its users. According to Dr. Smith, who estimates that at least 4 million adults have tried 7-OH, there are no confirmed human cases of respiratory depression caused by 7-OH. Additionally, reports of physical dependence or substance use disorder related to 7-OH are even rarer than those associated with kratom. 7-OH Is Not Causing Widespread Illness or Injury Dr. Boyer reviewed nationwide toxicology databases, including poison center data, and found limited evidence of acute overdose risk from 7-hydroxymitragynine. No deaths have been attributed to 7-hydroxymitragynine, a finding confirmed by America's Poison Center in their August 12, 2025 report. As Dr. Boyer stated, 'A signal arising from overdose death from 7-hydroxymitragynine is absent. Based upon data available at this time, given the degree of population exposure, the lack of findings suggests that 7-hydroxymitragynine carries no unreasonable risk of overdose death.' Dr. Monte arrived at the same conclusion as Dr. Boyer, that there is currently no evidence of a safety signal regarding 7-OH as reported by independent poison control and toxicology centers across the United States. Dr. Boyer also disagreed with the FDA's report regarding the putative safety or danger of 7-OH. According to Dr. Boyer, the FDA assessment relies on animal studies receiving intravenous 7-hydroxymitragynine (a route of administration never used in humans) and overlooks existing data indicating low bioavailability, rapid clearance, and poor brain penetration characteristic of oral 7-hydroxymitragynine. 7-OH is a Natural Product; Not Synthetic Opponents of 7-OH often mistakenly label these kratom-derived products as 'synthetic.' According to Dr. Prestwich, '7-OH is not manufactured synthetically.' Instead, 7-OH is a naturally occurring selective oxidation product of mitragynine, already present among the indole alkaloids in kratom plant extract. These products contain 7-OH that is chemically identical to the natural metabolite of mitragynine produced by the kratom plant and through metabolism in the human body. Thus, 7-OH is a natural product. Pre-Clinical Data Conducted by Shaman Botanicals Supports the Favorable Safety Profile of 7-OH Drs. Levine and Moskovitz each reviewed three preclinical studies commissioned by Shaman: (1) 'Acute Toxicity Assessment of 7-Hydroxymitragynine in Rodents,' (2) 'Pilot Safety Study of Escalating Doses of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Administered Daily for 7-day Intervals to Mature Dogs,' and (3) 'An In-Vitro Pre-Clinical Safety Comparison of Mitragynine and its Oxidative Metabolites: 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl.' In the two animal studies, no serious clinical toxicity or adverse events were observed. Dr. Levine stated these studies support initial safety and warrant further evaluation. Dr. Moskovitz concluded, 'Based on all the obtained data (i.e., in vitro studies, mice and dogs' models), it seems that the therapeutic potency and safety profile of 7HMG are either the same or better compared to mitragynine.' Current Science Supports a Reasonable Basis of Safety and Recommends Continued Study, Not Scheduling Full copies of each expert report have been provided to the FDA. 'The FDA pledged to follow the science. The aforementioned experts, some of the top scientists in the world, maintain the science supports a reasonable basis of safety in our 7-OH products,' said Sanders. Commitment to Transparency and Consumer Safety Shaman Botanicals remains deeply committed to transparency, scientific rigor, and consumer welfare. The company welcomes continued dialogue. About Holistic Alternative Recovery Trust (HART) Holistic Alternative Recovery Trust (HART) is a national nonprofit organization advocating for science-based policy, regulatory transparency, and access to safe, plant-based alternatives to opioids and other pharmaceuticals. 7-hydroxymitragynine (7-OH), a metabolite of mitragynine, the most abundant alkaloid found in kratom, is a new tool being used to combat opioid misuse and improve public health. HART strongly supports robust regulation to mandate that all 7-OH products are manufactured safely, are marketed transparently, and are kept out of the hands of children. Learn more at Media Contact HART Media [email protected] ### SOURCE: Holistic Alternative Recovery Trust (HART) Copyright 2025 EZ Newswire
Yahoo
2 days ago
- Yahoo
‘No Colon, Still Rollin'': Cass Bargell, US scrum-half and ostomy advocate, sets sights on World Cup
A few years ago, Cass Bargell gave a Ted Talk at Harvard, the same university where she studied integrative biology and played scrum-half, helping the Crimson to a national 15s title and earning nominations for US player of the year. Onstage, visibly nervous, she clutched a rugby ball as if for emotional support. 'I dropped the ball,' she says, laughing. 'They edited it out.' Bargell didn't drop the ball with her talk, which offered a compelling account of her traumatic experience with ulcerative colitis and her extraordinary recovery. It all began in late 2020, with alarming symptoms. Bargell kept playing through quickening pain but eventually, in November 2021, underwent ileostomy surgery to remove her colon and create a stoma, an opening in her abdomen to allow waste to pass. Just a few months later Bargell was back playing rugby, the sport she found as a middle-schooler in Summit, Colorado, as aggressive as ever but now wearing an ostomy bag. The title of her Ted Talk sums up her determination and her emergence as an advocate for life after surgery: No Colon, Still Rollin'. She has told her remarkable tale many times, including to former NFL Man of the Year and fellow patient Rolf Benirschke, for The Phoenix, official magazine of the United Ostomy Associations of America. But now, at 25 and eight times capped, Bargell is about to step onto the biggest stage of all – the 2025 Women's Rugby World Cup in England, where the US kick-off against the hosts on Friday. Speaking to the Guardian, she said that though life with an ostomy had not 'gotten any easier … I think I've gotten a lot better at handling it. 'I think some things have actually gotten harder, in some ways. The longer I've had it, the more it feels like this daunting thing that's gonna go on for ever. And I think I have, like, those big emotional moments, but I'm a lot better at handling it day to day. I don't think about my bag and I know how to change it much faster now. I know how to handle my supplies.' Related: World Cup final to be most attended women's rugby match in history after ticket sellout Bargell's play gives no clues of her extra burden. In Washington in July against Fiji, as the Americans struggled to hold a narrowing lead, the 5ft 4in dynamo forced two crucial turnovers, stealing Fijiana ball at the ruck. Turning to the nearest reporter to ask 'Who's that flanker the Eagles brought on?', the Guardian was swiftly enlightened: not only was Bargell not a forward, but also, 'that's nothing: she plays with an ostomy bag.' Asked if that played on her mind during games, she said: 'No, I don't think about it. But I'm really lucky that I'm supported by my coaches too. 'When I'm playing and I get hit in the bag, I don't feel anything, I don't think anything. I just put the ball back strongly. But if we're in training and we're doing a drill … where we come up and hit each other and then backpedal, reload, come up at each other again, backpedal, reload, just like working on the constant up and back, as the attacker I was just getting hit straight in the bag over and over and over, and I was like, this never happens to me in a game, and I'm really uncomfortable. 'I wasn't hurt from it or anything. I just was like, that's wearing my bag down more than I need. And my coaches are like, perfect. 'No problem. You'll hold the pad next time.' So then everyone was in the line and I just had a [tackle] pad, and it was fine. 'So it's not like I love getting hit in the bag repetitively. It's just that when it happens, it's not a big deal. I also feel like my right fend has gotten much stronger since I got my ostomy. I don't like people getting that close, so when I can avoid it, I do.' She laughs again, and switches from hand-offs to helping hands, saluting the influence of Ilona Maher, the US center, Olympic sevens medalist and social media star who has fired global interest in the women's game. 'Ilona, the version you see on the internet is how she is,' Bargell says. 'She's, like, a fun, big personality. And also everything she says about there needs to be more stars [in women's rugby] and we need to lift more women up, she lives that and walks it with us. She's helped me so much with sharing my story, with all the social media stuff and everything she talks about in that world. 'On the field, she's fast and she's powerful and she's strong and she can pass, and she brings so much to our team. I love training with her. She's also a really strong organizer, which I don't think people can always see, but she does communicate a lot and helps us all.' Bargell, Maher and the rest of the Eagles may need all the help they can get on Friday: England are favorites to win the World Cup, having crushed rivals France in their final warm-up while the US lost to Canada, another title contender. Looking at that game, Bargell identified a failing familiar from the meeting with Fiji in DC: a strong start not maintained. 'The first half felt easy,' says Bargell, who will start on the bench behind Olivia Ortiz on Friday. 'It felt like that's what we practiced in training, and it was just about executing it. 'We've been working a lot on finding our energy right after half-time and being able to come out and start the second half the way we started the first half, because it really wasn't like we weren't surprising ourselves with what we were doing that first half. It was what we practiced. And so it's just about finding a way to keep that energy throughout the whole game.' 'We really rise' Bargell is one of many Eagles who this year played in Women's Elite Rugby, the semi-pro league which has just completed its first season, with Bargell turning out for the Boston Banshees while working as a data analyst for the Crohn's and Colitis Foundation. She speaks favorably of WER as a step up from the amateur game, if not at the level of Premiership Women's Rugby, where senior Eagles including Ortiz play, where Maher shone for Bristol, and in which England's Red Roses ply their fearsome trade. 'I think an interesting part about our team is that we really rise,' Bargell says. 'We rise to the occasion. And so I know we'll rise [against England]. 'It's an incredible opportunity to be a part of that opening match at all, and I know everyone's really excited for it. We've honestly just been focused on building our own systems. It's not like these past three weeks were only focused on England.' True: Australia and Samoa also await, two wins most likely needed to make the quarter-finals. Australia offer the sterner test. In Perth in May, the Wallaroos downed the Eagles, 29-17. Bargell remains confident. 'We all believe we have a lot of threats, and like who we are as players,' she says. 'And so if we can bring our team together in that way, then we can compete.'